Medivir: An Option Deal with Rheos Medicines - Redeye
Redeye comments on the publication of a patent application by Medivir together with Rheos Medicines that is the result of a previous option deal. It shows how Medivir has been creating value from its legacy research portfolio.
ANNONS
Redeye comments on the publication of a patent application by Medivir together with Rheos Medicines that is the result of a previous option deal. It shows how Medivir has been creating value from its legacy research portfolio.